Intercostal Plane Block for Post Cardiac Surgery Pain
(EPOCH Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are using opioids or narcotics regularly, you may not be eligible to participate.
What data supports the effectiveness of the treatment Intermittent Superficial Parasternal Intercostal Plane Block, Naropin for post-cardiac surgery pain?
Research suggests that parasternal intercostal nerve blocks, like the superficial parasternal intercostal plane block, can help reduce pain and the need for opioids after cardiac surgery. However, the results vary due to differences in how the procedure is done, and more standardized studies are needed to confirm these benefits.12345
Is the intercostal plane block safe for humans?
The intercostal plane block, used for pain management after cardiac surgery, has been shown to reduce the need for opioids and their side effects, suggesting it is generally safe. However, differences in how the procedure is done can affect outcomes, so standardizing the technique is important for safety.12345
How does the intercostal plane block treatment differ from other treatments for post-cardiac surgery pain?
The intercostal plane block treatment is unique because it involves injecting a local anesthetic into specific intercostal spaces under ultrasound guidance to provide pain relief after cardiac surgery. This method aims to reduce the need for opioids and their side effects, offering a potentially more favorable pain management option compared to traditional systemic pain medications.12346
What is the purpose of this trial?
The goal of this clinical trial is to assess whether the use of intermittent superficial parasternal intercostal plane blocks reduces opioid usage in patients undergoing cardiac surgery with median sternotomy.Participants randomized to the intervention group will receive the blocks with 0.2% ropivacaine administered via catheters placed in the superficial parasternal intercostal plane bilaterally under ultrasound guidance. Researchers will compare this group with a control group given 0.9% saline through similarly placed catheters. The primary outcome will be cumulative postoperative opioid use (measured as Milligram Morphine Equivalent (MME)) up to 72 hours following catheter insertion.
Research Team
Ahmad Alli, MD
Principal Investigator
Unity Health Toronto
Eligibility Criteria
This trial is for adults having heart surgery through a cut down the middle of their chest (median sternotomy). It's not for those who've had this type of surgery before, are in unstable condition, weigh less than 50kg, are pregnant or nursing, use opioids long-term or have chronic pain disorders. People with allergies to certain anesthetics or unable to follow the study rules can't join either.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intermittent superficial parasternal intercostal plane blocks with either 0.2% ropivacaine or 0.9% saline
Follow-up
Participants are monitored for safety and effectiveness after treatment, including pain assessment and opioid use
Post-operative Recovery
Assessment of quality of recovery using Quality of Recovery-15 Scale
Treatment Details
Interventions
- Intermittent Superficial Parasternal Intercostal Plane Block
Find a Clinic Near You
Who Is Running the Clinical Trial?
Unity Health Toronto
Lead Sponsor